國立高雄大學圖資館 |

Language: English

Back

Immunotherapy of hepatocellular carc...

Greten, Tim F.

Immunotherapy of hepatocellular carcinoma

Record Type:	Electronic resources : Monograph/item
Title/Author:	Immunotherapy of hepatocellular carcinomaedited by Tim F. Greten.
other author:	Greten, Tim F.
Published:	Cham :Springer International Publishing :2017.
Description:	x, 167 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	LiverCancer
Online resource:	http://dx.doi.org/10.1007/978-3-319-64958-0
ISBN:	9783319649580$q(electronic bk.)

Immunotherapy of hepatocellular carcinoma
Immunotherapy of hepatocellular carcinoma[electronic resource] /edited by Tim F. Greten. - Cham :Springer International Publishing :2017. - x, 167 p. :ill., digital ;24 cm.

Preface -- Introduction -- Vaccine approaches -- Spontaneous Immune responses to ablative therapies -- Antigen-specific T cell responses. Immune checkpoint inhibitors -- NASH and HCC -- Cytokine activated killer cells -- Sorafenib combination therapy -- Glypican 3 -- Suppressor cells -- Cytokines in HCC pathogenesis and treatment -- Index.

In this book we provide insights into liver - cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical "inflammation-induced" cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.

ISBN: 9783319649580$q(electronic bk.)

Standard No.: 10.1007/978-3-319-64958-0doiSubjects--Topical Terms:

794374
Liver
--Cancer

LC Class. No.: RC280.L5

Dewey Class. No.: 616.9943606

Immunotherapy of hepatocellular carcinoma
LDR:02565nmm a2200313 a 4500 001 523270
003 DE-He213
005 20180419142526.0
006 m d
007 cr nn 008maaau
008 180628s2017 gw s 0 eng d
020 $a 9783319649580$q(electronic bk.)
020 $a 9783319649573$q(paper)
024 7 $a 10.1007/978-3-319-64958-0 $2 doi
035 $a 978-3-319-64958-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L5
072 7 $a MBGR $2 bicssc
072 7 $a MED000000 $2 bisacsh
082 0 4 $a 616.9943606 $2 23
090 $a RC280.L5 $b I33 2017
245 0 0 $a Immunotherapy of hepatocellular carcinoma $h [electronic resource] / $c edited by Tim F. Greten.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2017.
300 $a x, 167 p. : $b ill., digital ; $c 24 cm.
505 0 $a Preface -- Introduction -- Vaccine approaches -- Spontaneous Immune responses to ablative therapies -- Antigen-specific T cell responses. Immune checkpoint inhibitors -- NASH and HCC -- Cytokine activated killer cells -- Sorafenib combination therapy -- Glypican 3 -- Suppressor cells -- Cytokines in HCC pathogenesis and treatment -- Index.
520 $a In this book we provide insights into liver - cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical "inflammation-induced" cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
650 0 $a Liver $x Cancer $x Immunotherapy. $3 794374
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Biomedicine general. $3 273948
700 1 $a Greten, Tim F. $3 794373
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-64958-0
950 $a Biomedical and Life Sciences (Springer-11642)